​

CRISPR Therapeutics (CRSP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CRSP Stock Forecast

CRISPR Therapeutics stock forecast is as follows: an average price target of $77.50 (represents a 92.16% upside from CRSP’s last price of $40.33) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

CRSP Price Target

The average price target for CRISPR Therapeutics (CRSP) is $77.50 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $100.00 to $59.00. This represents a potential 92.16% upside from CRSP's last price of $40.33.

CRSP Analyst Ratings

Buy

According to 12 Wall Street analysts, CRISPR Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CRSP stock is 0 'Strong Buy' (0.00%), 8 'Buy' (66.67%), 3 'Hold' (25.00%), 1 'Sell' (8.33%), and 0 'Strong Sell' (0.00%).

CRISPR Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 06, 2024Jay OlsonOppenheimer$95.00$49.5191.88%135.56%
Nov 05, 2024Rick BienkowskiLeerink Partners$67.00$50.3633.04%66.13%
Aug 12, 2024Joon LeeTruist Financial$100.00$46.55114.82%147.95%
Aug 06, 2024Gil BlumNeedham$84.00$50.1167.63%108.28%
Aug 06, 2024Benjamin BurnettStifel Nicolaus$59.00$50.0117.98%46.29%
Aug 06, 2024Luca IssiRBC Capital$60.00$50.1319.70%48.77%
May 09, 2024Jack AllenRobert W. Baird$52.00$53.29-2.42%28.94%
Nov 23, 2022Citigroup$63.00$55.7213.07%56.21%
Aug 09, 2022Geulah LivshitsChardan Capital$79.30$81.39-2.57%96.63%
Jun 17, 2022Kostas BiliourisBMO Capital$98.00$70.7338.56%143.00%
Apr 28, 2022Credit Suisse$78.00$51.9650.12%93.40%
Feb 16, 2022Gil BlumNeedham$170.00$61.97174.33%321.52%
Feb 15, 2022Rick BienkowskiLeerink Partners$120.00$60.9796.82%197.55%
Jan 07, 2022Yanan ZhuWells Fargo$105.00$67.6655.19%160.35%
Nov 04, 2021Jay OlsonOppenheimer$172.00$93.0084.95%326.48%
Oct 12, 2021Edward TenthoffPiper Sandler$180.00$102.5975.46%346.32%
Aug 16, 2021Arlinda LeeCanaccord Genuity$160.00$122.5530.56%296.73%
Jun 11, 2021Anthony ButlerRoth Capital$171.00$127.0034.65%324.00%
Apr 21, 2021Maury RaycroftJefferies$172.00$124.9337.68%326.48%

The latest CRISPR Therapeutics stock forecast, released on Nov 06, 2024 by Jay Olson from Oppenheimer, set a price target of $95.00, which represents a 91.88% increase from the stock price at the time of the forecast ($49.51), and a 135.56% increase from CRSP last price ($40.33).

CRISPR Therapeutics Price Target by Period

1M3M12M
# Anlaysts-27
Avg Price Target-$81.00$73.86
Last Closing Price$40.33$40.33$40.33
Upside/Downside-100.00%100.84%83.14%

In the current month, the average price target of CRISPR Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CRISPR Therapeutics's last price of $40.33. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024Leerink PartnersOutperformOutperformHold
Aug 06, 2024Cowen & Co.SellSellHold
Aug 06, 2024NeedhamBuyBuyHold
Aug 06, 2024RBC CapitalSector PerformSector PerformHold
Jun 17, 2024Piper SandlerOverweightOverweightHold
Apr 18, 2024CitigroupBuyBuyHold
Feb 15, 2024Wolfe ResearchPeer PerformInitialise
Dec 11, 2023JMP SecuritiesMarket OutperformMarket OutperformHold
Oct 17, 2023Cantor FitzgeraldOverweightNeutralDowngrade
Aug 17, 2023CitigroupNeutralBuyUpgrade
Jun 09, 2023JMP SecuritiesMarket OutperformMarket OutperformHold
Apr 13, 2023Cantor FitzgeraldOverweightInitialise
Nov 23, 2022CitigroupNeutralNeutralHold
Aug 16, 2022CitigroupNeutralNeutralHold
Aug 09, 2022Chardan CapitalBuyBuyHold
Jun 23, 2022OppenheimerOutperformOutperformHold
Jun 22, 2022Piper SandlerOverweightOverweightHold
Jun 22, 2022Chardan CapitalBuyBuyHold
Jun 17, 2022BMO CapitalOutperformInitialise
May 17, 2022CitigroupNeutralNeutralHold
Apr 28, 2022Credit SuisseNeutralInitialise

CRISPR Therapeutics's last stock rating was published by Leerink Partners on Nov 05, 2024. The company gave CRSP a "Outperform" rating, the same as its previous rate.

CRISPR Therapeutics Financial Forecast

CRISPR Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue--------------$70.00M$100.00M$6.00K$94.00K$158.00K$178.00K$12.90M$824.00K$900.70M$539.00K$370.00K$148.00K$44.00K$157.00K$77.02M$211.93M
Avg Forecast$602.80K$602.71K$602.62K$602.53K$31.70M$24.09M$18.27M$12.32M$7.97M$6.57M$12.06M$24.34M$140.94M$11.89M$1.80M$25.85M$7.12M$1.85M$2.21M$2.80M$2.19M$1.23M$900.19M$1.40M$2.20M$1.92M$18.13M$3.02M$45.21M$6.15M
High Forecast$1.55M$1.55M$1.55M$1.55M$81.76M$62.14M$47.12M$31.79M$29.84M$16.94M$12.18M$24.93M$204.13M$30.67M$4.64M$66.68M$18.38M$1.85M$2.21M$2.80M$2.19M$1.23M$900.19M$1.40M$2.20M$1.92M$18.13M$3.02M$45.21M$6.15M
Low Forecast$32.00K$31.99K$31.99K$31.98K$1.68M$1.28M$969.54K$654.16K$575.85K$348.57K$11.93M$23.75M$132.69K$631.08K$95.53K$1.37M$378.10K$1.85M$2.21M$2.80M$2.19M$1.23M$900.19M$1.40M$2.20M$1.92M$18.13M$3.02M$45.21M$6.15M
# Analysts33454527149749181591016810991399159988
Surprise %--------------38.89%3.87%0.00%0.05%0.07%0.06%5.90%0.67%1.00%0.39%0.17%0.08%0.00%0.05%1.70%34.44%

CRISPR Therapeutics's average Quarter revenue forecast for Sep 23 based on 18 analysts is $11.89M, with a low forecast of $631.08K, and a high forecast of $30.67M. CRSP's average Quarter revenue forecast represents a -83.02% decrease compared to the company's last Quarter revenue of $70.00M (Jun 23).

CRISPR Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527149749181591016810991399159988
EBITDA-------------$-132.41M$-90.26M$-64.49M$-131.54M$-177.37M$-183.26M$-169.93M$-137.24M$-122.42M$767.02M$-109.87M$-104.62M$-89.90M$-77.08M$-67.26M$31.98M$139.98M
Avg Forecast$-233.84K$-233.80K$-233.77K$-233.73K$-12.30M$-9.35M$-7.09M$-4.78M$-3.09M$-2.55M$-4.68M$-119.21M$-54.67M$-4.61M$-698.21K$-127.49M$-120.94M$-730.58K$-874.98K$-136.36M$-864.22K$-484.45K$-356.00M$-106.88M$-871.35K$-760.62K$-7.17M$-60.86M$-17.88M$-2.43M
High Forecast$-12.41K$-12.41K$-12.41K$-12.41K$-652.62K$-496.02K$-376.10K$-253.76K$-223.38K$-135.22K$-4.63M$-95.36M$-51.47K$-244.81K$-37.06K$-101.99M$-96.76M$-730.58K$-874.98K$-109.08M$-864.22K$-484.45K$-356.00M$-85.51M$-871.35K$-760.62K$-7.17M$-48.69M$-17.88M$-2.43M
Low Forecast$-603.21K$-603.12K$-603.03K$-602.94K$-31.72M$-24.11M$-18.28M$-12.33M$-11.58M$-6.57M$-4.73M$-143.05M$-79.19M$-11.90M$-1.80M$-152.99M$-145.13M$-730.58K$-874.98K$-163.63M$-864.22K$-484.45K$-356.00M$-128.26M$-871.35K$-760.62K$-7.17M$-73.03M$-17.88M$-2.43M
Surprise %-------------28.71%129.28%0.51%1.09%242.78%209.45%1.25%158.80%252.71%-2.15%1.03%120.07%118.20%10.75%1.11%-1.79%-57.52%

9 analysts predict CRSP's average Quarter EBITDA for Sep 21 to be $-484.45K, with a high of $-484.45K and a low of $-484.45K. This is -100.06% lower than CRISPR Therapeutics's previous annual EBITDA (Jun 21) of $767.02M.

CRISPR Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527149749181591016810991399159988
Net Income-------------$-112.15M$-77.74M$-53.06M$-110.58M$-174.55M$-185.83M$-179.22M$-141.25M$-127.15M$759.23M$-113.16M$-107.04M$-92.44M$-79.66M$-69.73M$30.54M$138.42M
Avg Forecast$-40.91M$-54.50M$-92.85M$-95.66M$-101.10M$-104.07M$-114.49M$-116.61M$-104.71M$-118.02M$-121.67M$-125.99M$5.65M$-169.55M$-181.32M$-134.75M$-124.48M$-193.43M$-188.23M$-144.11M$-149.82M$-148.85M$299.13M$-110.08M$-108.11M$-100.63M$-80.74M$-63.09M$-47.88M$-38.79M
High Forecast$9.45M$12.59M$21.45M$22.10M$23.36M$24.04M$26.45M$-83.99M$-64.57M$27.26M$28.11M$-100.79M$29.25M$-63.47M$41.88M$-107.80M$-99.58M$-193.43M$-188.23M$-115.29M$-149.82M$-148.85M$299.13M$-88.07M$-108.11M$-100.63M$-80.74M$-50.47M$-47.88M$-38.79M
Low Forecast$-124.91M$-166.43M$-283.53M$-292.10M$-308.72M$-317.79M$-349.59M$-140.26M$-168.41M$-360.39M$-371.52M$-151.18M$-14.13M$-206.07M$-553.65M$-161.69M$-149.37M$-193.43M$-188.23M$-172.94M$-149.82M$-148.85M$299.13M$-132.10M$-108.11M$-100.63M$-80.74M$-75.71M$-47.88M$-38.79M
Surprise %-------------0.66%0.43%0.39%0.89%0.90%0.99%1.24%0.94%0.85%2.54%1.03%0.99%0.92%0.99%1.11%-0.64%-3.57%

CRISPR Therapeutics's average Quarter net income forecast for Sep 21 is $-148.85M, with a range of $-148.85M to $-148.85M. CRSP's average Quarter net income forecast represents a -119.61% decrease compared to the company's last Quarter net income of $759.23M (Jun 21).

CRISPR Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527149749181591016810991399159988
SG&A-------------$18.29M$19.03M$22.36M$21.17M$27.00M$26.27M$28.02M$24.13M$24.35M$29.81M$24.52M$25.77M$21.54M$21.35M$19.55M$17.27M$15.52M
Avg Forecast$47.98M$47.97M$47.97M$47.96M$2.52B$1.92B$1.45B$981.01M$634.42M$522.73M$959.60M$19.70M$11.22B$946.38M$143.27M$21.07M$567.01M$147.05M$176.11M$222.90M$173.95M$97.51M$71.65B$111.27M$175.38M$153.09M$1.44B$240.56M$3.60B$489.86M
High Forecast$123.77M$123.76M$123.74M$123.72M$6.51B$4.95B$3.75B$2.53B$2.38B$1.35B$969.81M$23.64M$16.25B$2.44B$369.58M$25.28M$1.46B$147.05M$176.11M$222.90M$173.95M$97.51M$71.65B$111.27M$175.38M$153.09M$1.44B$240.56M$3.60B$489.86M
Low Forecast$2.55M$2.55M$2.55M$2.55M$133.91M$101.78M$77.17M$52.07M$45.84M$27.75M$949.38M$15.76M$10.56M$50.23M$7.60M$16.85M$30.10M$147.05M$176.11M$222.90M$173.95M$97.51M$71.65B$111.27M$175.38M$153.09M$1.44B$240.56M$3.60B$489.86M
Surprise %-------------0.02%0.13%1.06%0.04%0.18%0.15%0.13%0.14%0.25%0.00%0.22%0.15%0.14%0.01%0.08%0.00%0.03%

CRISPR Therapeutics's average Quarter SG&A projection for Dec 23 is $11.22B, based on 9 Wall Street analysts, with a range of $10.56M to $16.25B. The forecast indicates a 61235.77% rise compared to CRSP last annual SG&A of $18.29M (Sep 23).

CRISPR Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts33454527149749181591016810991399159988
EPS-------------$-1.41$-0.98$-0.67$-1.41$-2.24$-2.40$-2.32$-1.84$-1.67$10.01$-1.51$-1.53$-1.32$-1.30$-1.15$0.53$2.52
Avg Forecast$-0.48$-0.64$-1.09$-1.12$-1.19$-1.22$-1.34$-1.37$-1.23$-1.38$-1.43$-1.36$0.07$-1.99$-2.13$-1.74$-2.25$-2.28$-2.22$-1.94$-1.76$-1.75$3.52$-1.47$-1.27$-1.18$-0.95$-1.06$-0.56$-0.46
High Forecast$0.11$0.15$0.25$0.26$0.27$0.28$0.31$-0.99$-0.76$0.32$0.33$0.31$0.34$-0.74$0.49$0.40$0.52$-2.28$-2.22$-1.94$-1.76$-1.75$3.52$-1.47$-1.27$-1.18$-0.95$-1.06$-0.56$-0.46
Low Forecast$-1.47$-1.95$-3.33$-3.43$-3.62$-3.73$-4.10$-1.65$-1.98$-4.23$-4.36$-4.15$-0.17$-2.42$-6.50$-5.32$-6.87$-2.28$-2.22$-1.94$-1.76$-1.75$3.52$-1.47$-1.27$-1.18$-0.95$-1.06$-0.56$-0.46
Surprise %-------------0.71%0.46%0.38%0.63%0.98%1.08%1.20%1.04%0.95%2.84%1.03%1.20%1.11%1.37%1.09%-0.94%-5.52%

According to 9 Wall Street analysts, CRISPR Therapeutics's projected average Quarter EPS for Sep 21 is $-1.75, with a low estimate of $-1.75 and a high estimate of $-1.75. This represents a -117.51% decrease compared to CRSP previous annual EPS of $10.01 (Jun 21).

CRISPR Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.52$70.0013361.54%Buy
EDITEditas Medicine$1.52$10.20571.05%Buy
NTLAIntellia Therapeutics$13.13$53.00303.66%Buy
FATEFate Therapeutics$1.88$5.00165.96%Buy
VERVVerve Therapeutics$5.61$14.00149.55%Buy
BEAMBeam Therapeutics$28.58$55.0092.44%Buy
CRSPCRISPR Therapeutics$44.63$77.5073.65%Buy
CRBUCaribou Biosciences$1.94$3.0054.64%Buy
REGNRegeneron Pharmaceuticals$740.01$1.14K53.40%Buy
SRPTSarepta Therapeutics$125.76$187.2048.85%Buy
NVONovo Nordisk$108.01$158.0046.28%Buy
KRYSKrystal Biotech$169.04$210.3324.43%Buy

CRSP Forecast FAQ

Is CRISPR Therapeutics a good buy?

Yes, according to 12 Wall Street analysts, CRISPR Therapeutics (CRSP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 66.67% of CRSP's total ratings.

What is CRSP's price target?

CRISPR Therapeutics (CRSP) average price target is $77.5 with a range of $59 to $100, implying a 92.16% from its last price of $40.33. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will CRISPR Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CRSP stock, the company can go up by 92.16% (from the last price of $40.33 to the average price target of $77.5), up by 147.95% based on the highest stock price target, and up by 46.29% based on the lowest stock price target.

Can CRISPR Therapeutics stock reach $60?

CRSP's average twelve months analyst stock price target of $77.5 supports the claim that CRISPR Therapeutics can reach $60 in the near future.

What are CRISPR Therapeutics's analysts' financial forecasts?

CRISPR Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $86.38M (high $222.82M, low $4.58M), average EBITDA is $-33.507M (high $-1.779M, low $-86.436M), average net income is $-436M (high $-10.152M, low $-1.116B), average SG&A $6.88B (high $17.74B, low $364.94M), and average EPS is $-5.119 (high $-0.119, low $-13.097). CRSP's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.41M (high $6.22M, low $127.95K), average EBITDA is $-935K (high $-49.633K, low $-2.412M), average net income is $-284M (high $65.59M, low $-867M), average SG&A $191.88M (high $494.99M, low $10.18M), and average EPS is $-3.331 (high $0.769, low $-10.172).

Did the CRSP's actual financial results beat the analysts' financial forecasts?

Based on CRISPR Therapeutics's last annual report (Dec 2022), the company's revenue was $436K, which missed the average analysts forecast of $13.98M by -96.88%. Apple's EBITDA was $-673M, beating the average prediction of $-259M by 160.00%. The company's net income was $-650M, missing the average estimation of $-650M by -0.01%. Apple's SG&A was $102.46M, missing the average forecast of $1.11B by -90.79%. Lastly, the company's EPS was $-8.36, missing the average prediction of $-8.684 by -3.73%. In terms of the last quarterly report (Jun 2023), CRISPR Therapeutics's revenue was $70M, beating the average analysts' forecast of $1.8M by 3789.13%. The company's EBITDA was $-90.262M, beating the average prediction of $-698K by 12827.61%. CRISPR Therapeutics's net income was $-77.74M, missing the average estimation of $-181M by -57.12%. The company's SG&A was $19.03M, missing the average forecast of $143.27M by -86.72%. Lastly, the company's EPS was $-0.98, missing the average prediction of $-2.127 by -53.93%